IB001
IB001 is a humanized anti-BAG3 antibody that inhibits BAG3, with a KD value of 14.4 nM for human BAG3. IB001 blocks BAG3-dependent monocyte/macrophage activation, interferes with the interaction between BAG3 and IFITM-2, and disrupts tumor microenvironment signaling pathways. IB001 inhibits tumor growth, reduces α-SMA-positive fibroblasts, and blocks BAG3-dependent IL-6 release. IB001 accumulates in a time-dependent manner in pancreatic ductal adenocarcinoma tumors. IB001 can be used for research related to pancreatic ductal adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
|
HSP70 |
IB001 (BAG3-H2L4) binds to purified recombinant human BAG3 protein with a Kd of 14.4 nM[1].
IB001 inhibits binding of FITC-labeled recombinant human BAG3 to murine J774A.1 macrophage cells[1].
IB001 (9.37-300 μg/mL; 16 h) dose-dependently inhibits recombinant human BAG3-induced IL-6 production by isolated human CD14+ monocytes[1].
IB001 (200 μg/mL; 16 h) significantly inhibits PANC-1 pancreatic cancer cell conditioned medium-induced IL-6 production by isolated human CD14+ monocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
IB001 (20 mg/kg; daily; 7 days) does not induce cardiotoxicity in 6-month-old athymic nude-Foxn1 nu/nu mice after 7 days of daily treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 nu/nu (female, 6 weeks old, injected with MIA PaCa-2 cells)[1]
-
Dosage:20 mg/kg
-
Administration:every 48 h; twice a week
-
Result:Achieved significant tumor growth inhibition, with final tumor volume reaching ~400% of initial volume compared to ~1000% in vehicle controls.
Reduced α-SMA-positive fibroblast area in tumor tissue from ~3.5% in vehicle-treated mice to <0.5%.
-
Animal Model:Athymic nude-Foxn1 nu/nu (6 months old)[1]
-
Dosage:20 mg/kg
-
Administration:daily; 7 days
-
Result:Showed no adverse effect on ejection fraction, shortening fraction, or strain percentage.
O95817
BAG3
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
BAG3-H2L4
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IB001 Related Classifications
HY-P992379 Related Classifications
Powered by Bioz